<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Neboglamine</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Neboglamine</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/7/7e/Neboglamine.svg"/></li>
<li>Another names: CR-2249, XY-2401 and Nebostinel.</li>
<li>Positive allosteric modulator of the glycine site of the NMDA receptor, which is linked to improved cognition and memory.</li>
<li>Also shows potential as an antipsychotic, particularly for schizophrenia and cocaine dependence, by increasing neuronal activity in key brain areas like the prefrontal cortex.</li>
<li>Safe dose range of 10 to 600 mg per day.</li>
<li>Preferred range of 30 to 300 mg per day.</li>
<li><a href="https://drugs.ncats.io/drug/12EA34U5B8">Research</a> suggests it enhances cognition and memory, as demonstrated in animal models, where it shows cognition- and memory-enhancing effects.</li>
<li>Studies showing it increases neuronal activation in areas relevant to schizophrenia, potentially addressing negative and cognitive symptoms.</li>
<li>Binds very weakly to the NMDA receptor recognition site (IC50 0.7 mM) and shows no significant binding affinity to AMPA and kainic receptors, suggesting a selective action at the glycine site (<a href="https://drugs.ncats.io/drug/12EA34U5B8">source</a>).</li>
<li>Antipsychotic-like effects are further evidenced by its ability to inhibit phencyclidine (PCP)-induced hyperlocomotion and rearing behavior in rat models, supporting its clinical evaluation for schizophrenia treatment.</li>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main></body></html>